文献速递类风湿关节炎脊柱关节炎

加拿大不列颠哥伦比亚省新起始与转换政策后生物类似药英夫利西单抗和依那西普的 uptake 与支出:一项中断时间序列分析

Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-03-04

该研究利用加拿大不列颠哥伦比亚省2013年1月至2020年11月的行政索赔数据,纳入208,984例患有类风湿关节炎、强直性脊柱炎、银屑病关节炎和/或斑块状银屑病且符合公共药物覆盖条件的居民,其中5,884例使用英夫利西单抗或依那西普。中断时间序列分析显示,强制转换政策较新起始政策更能持续提高生物类似药处方比例和支出比例。

要点

  • 新起始政策后生物类似药依那西普处方比例每月小幅逐渐增加0.65%(95%CI 0.44, 0.85)。
  • 转换政策后生物类似药依那西普和英夫利西单抗处方比例分别持续增加76.98%(95%CI 75.56, 78.41)和58.43%(95%CI 52.11, 64.75)。
  • 作者结论认为强制转换政策在提高生物类似药使用方面比新起始政策有效得多。

核心结论

  • 作者发现强制转换政策在提高生物类似药药物使用方面比新起始政策有效得多。

研究设计与样本

  • 研究使用行政索赔数据识别2013年1月至2020年11月期间符合公共药物覆盖条件的加拿大不列颠哥伦比亚省≥18岁居民,患有类风湿关节炎、强直性脊柱炎、银屑病关节炎和/或斑块状银屑病。
  • 研究采用中断时间序列分析,评估新起始政策和生物类似药转换政策实施后,生物类似药英夫利西单抗和依那西普在对应药物总处方和总支出中所占比例的变化。
  • 研究共纳入208,984例患有类风湿关节炎、强直性脊柱炎、斑块状银屑病和/或银屑病关节炎的个体,对应5,884例使用英夫利西单抗和依那西普的患者。

主要发现

  • 新起始政策后,生物类似药依那西普处方比例每月小幅逐渐增加0.65%(95%CI 0.44, 0.85)。
  • 新起始政策后,生物类似药依那西普总支出比例趋势也增加0.51%(95%CI 0.28, 0.73)。
  • 转换政策后,生物类似药依那西普和英夫利西单抗处方比例分别持续增加76.98%(95%CI 75.56, 78.41)和58.43%(95%CI 52.11, 64.75)。
  • 转换政策后,生物类似药依那西普和英夫利西单抗月度支出分别持续增加78.22%(95%CI 76.65, 79.79)和71.23%(95%CI 66.82, 75.65)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Uptake of biosimilars has been suboptimal in North America. This study was undertaken to quantify the impact of various policy interventions (namely, new start and switching policies) on uptake and spending on biosimilar infliximab and etanercept in British Columbia (BC), Canada. METHODS: We used administrative claims data to identify BC residents ≥18 years of age with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and/or plaque psoriasis who qualified for public drug coverage from January 2013 to November 2020. Using interrupted time series analysis, we studied the change in proportion spent on and prescriptions dispensed of biosimilar infliximab and etanercept out of the total amount per agent after new start and biosimilar switching policies were implemented. RESULTS: Our study included 208,984 individuals living with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and/or psoriatic arthritis, corresponding to 5,884 patients taking infliximab and etanercept. After the new start policy, we detected a small gradual increase in the proportion of dispensed biosimilar etanercept prescriptions of 0.65% per month (95% confidence interval [95% CI] 0.44, 0.85). The trend related to the proportion of total spending on biosimilar etanercept also increased (0.51% [95% CI 0.28, 0.73]). After the switching policy, there was a sustained increase in the proportion of dispensed biosimilar etanercept and infliximab prescriptions of 76.98% (95% CI 75.56, 78.41) and 58.43% (95% CI 52.11, 64.75), respectively. Similarly, there was a persistent increase in monthly spending on biosimilar etanercept and infliximab of 78.22% (95% CI 76.65, 79.79) and 71.23% (95% CI 66.82, 75.65), respectively. CONCLUSION: We found that mandatory switching policies were much more effective than new starting policies for increasing the use of biosimilar medications.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. McClean AR, Cheng L, Bansback N, et al. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis. Arthritis Care Res (Hoboken). 2023. PMID: 36752358. doi:10.1002/acr.25099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。